Leerink Partnrs Forecasts Stronger Earnings for REGENXBIO

REGENXBIO Inc. (NASDAQ:RGNX) – Equities research analysts at Leerink Partnrs boosted their FY2027 EPS estimates for REGENXBIO in a research note issued on Monday, November 18th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings per share of ($1.25) for the year, up from their prior estimate of ($1.87). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO’s FY2028 earnings at $1.10 EPS.

A number of other analysts have also commented on RGNX. Raymond James reissued an “outperform” rating and set a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. Chardan Capital reiterated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a report on Wednesday. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Morgan Stanley reiterated an “overweight” rating and issued a $22.00 target price on shares of REGENXBIO in a research note on Friday, November 15th. Finally, HC Wainwright lowered their target price on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a report on Thursday. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, REGENXBIO has a consensus rating of “Moderate Buy” and an average price target of $35.27.

REGENXBIO Price Performance

RGNX opened at $9.59 on Thursday. REGENXBIO has a fifty-two week low of $8.53 and a fifty-two week high of $28.80. The firm has a market capitalization of $475.14 million, a PE ratio of -1.91 and a beta of 1.23. The company’s 50-day moving average is $10.31 and its 200 day moving average is $12.12.

Insider Activity

In other news, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $11.56, for a total transaction of $115,600.00. Following the completion of the transaction, the director now owns 11,286 shares in the company, valued at approximately $130,466.16. This represents a 46.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 13.13% of the company’s stock.

Institutional Investors Weigh In On REGENXBIO

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC purchased a new position in shares of REGENXBIO in the first quarter worth about $304,000. Swiss National Bank boosted its holdings in REGENXBIO by 4.5% in the 1st quarter. Swiss National Bank now owns 81,500 shares of the biotechnology company’s stock worth $1,717,000 after buying an additional 3,500 shares during the period. ProShare Advisors LLC grew its stake in REGENXBIO by 8.3% in the 1st quarter. ProShare Advisors LLC now owns 11,384 shares of the biotechnology company’s stock valued at $240,000 after buying an additional 874 shares in the last quarter. State Board of Administration of Florida Retirement System raised its holdings in REGENXBIO by 33.3% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,485 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 3,870 shares during the period. Finally, Vanguard Group Inc. raised its holdings in REGENXBIO by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company’s stock valued at $102,756,000 after acquiring an additional 436,043 shares during the period. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.